8 results about "Protease resistant" patented technology

The present invention provides a Pediococcus pentosaceus ( Pediococcus pentosus ) strain ZPP083, which is deposited with the General Microbiology Center of the China National Center for Microbiological Culture Collection under the CGMCC No. 31944. The Pediococcus pentosaceus provided by the present invention has a strong antibacterial effect and produces a novel Class IIa bacteriocin with acid, heat, and protease resistance. The present invention also constructs a genetically engineered bacterium using this bacteriocin, increasing its expression.

The present application relates to the field of agricultural husbandry and veterinary technology, in particular to a protease-resistant antibacterial peptide FR and application thereof. The present application provides a protease-resistant antibacterial peptide FR, and the amino acid sequence of the antibacterial peptide FR is shown as SEQ ID NO. 1. The results of the specific implementation of the present application show that the protease-resistant antibacterial peptide FR provided by the present application has the activity of resisting gram-negative bacteria (Escherichia coli, Shigella flexneri, Salmonella and Campylobacter jejuni, etc.), has low hemolytic activity, can resist the cleavage of high-concentration protease, and has very good application prospect. In summary, the antibacterial peptide FR provided by the present application has the advantages of resisting gastrointestinal environment, resisting high salt and resisting protease cleavage, can realize the killing effect on gram-negative bacteria in the presence of enzymes and salt ions, and has the characteristics of low hemolytic activity, thereby providing a new way for the development of antibiotic substitutes.

The present invention relates to recombinant proteins having an amino acid sequence corresponding to or related to the thrombospondin type 1 repeat homology domain of a member of the CCN family proteins and the use thereof. Furthermore, the present invention relates to fusion proteins comprising an amino acid sequence corresponding to or related to the thrombospondin type 1 repeat homology domain of a member of the CCN family proteins combined with a fusion partner and optionally a linker region. Also, novel protease resistant Fc-fragments are disclosed herein.

The present application relates to a lactobacillus johnsonii producing a novel class III bacteriocin, an engineered bacterium and application thereof, and belongs to the technical field of microorganisms. Lactobacillus johnsonii The JLJ071 strain of the lactobacillus johnsonii is preserved in the China General Microbiological Culture Collection Center, and the preservation number is CGMCC No.34541. The bacteriocin amino acid sequence is shown in Seq ID No.1. The expressed novel class III bacteriocin has good bactericidal activity on listeria monocytogenes and salmonella pullorum, and has good characteristics such as acid resistance, high temperature resistance and protease resistance, and has a good application prospect in feed additives.

The present application provides modified Chymotrypsin-like ELAstase 2A (CELA2A) proteins such as catalytically inactivate and protease resistant CELA2A proteins. Also provided herein are the uses of the CELA2A proteins for preserving pancreatic islet size, number as well as enhancing insulin secreting and insulin signaling and for the treatment of diabetes, pancreatitis and other related diseases.

The invention provides a cosmetic application of a cyclic polypeptide, the cyclic polypeptide is H-Cys-Tyr-Val-Gln-Arg-Lys-Arg-Gln-Lys-Leu-Met-Pro-Cys-Lys (Met-Pro-D-Ph-Arg-D-Trp-Ph-Lys-Pro-Val-PEG5CH2CO)-NH2 (1, 13 disulfide bond cyclization), and the cyclic polypeptide is used for preparing a cosmetic skin care product which is used for breaking sensitive circulation and controlling hyperpigmentation and has the effects of resisting allergy and whitening at the same time. The cyclic polypeptide is prepared into a product through a supramolecular liposome infiltration promotion technology, is resistant to protease degradation and takes effect for a long time. According to the cosmetic application of the annular polypeptide and the supramolecular liposome product of the annular polypeptide, multiple key receptors can be targeted at the same time, sensitive circulation can be broken through, chromatosis can be controlled, meanwhile, the anti-allergic and whitening effects are achieved, and the multiple skin problems faced by people with sensitive skin can be solved in cooperation with an efficient delivery system.

A protease-resistant ADAMTS13 mutant protein or nucleic acid encoding the ADAMTS13 mutant protein is provided. The ADAMTS13 mutant protein comprises a mammalian ADAMTS13 protein in which one or more protease cleavage sites within the protein are replaced with amino acid sequence that is resistant to protease cleavage, and the mutant protein retains von Willebrand factor (VWF)-cleaving activity. The protease-resistant ADAMTS13 mutant is useful as a thrombolytic agent to treat common thrombotic disorders, including stroke, myocardial infarction, venous thromboembolism, and rare microvascular thrombotic disorders like thrombotic thrombocytopenia purpura (TTP).

The invention provides a Pediococcus pentosaceus ZPP083 strain, which is preserved in the General Microbiological Culture Collection Center of the China Committee for Culture Collection of Microorganisms, and the preservation number is CGMCC No.31944. The Pediococcus pentosaceus ZPP083 strain has the advantages that the Pediococcus pentosaceus ZPP083 strain can be used for preparing the Pediococcus pentosaceus ZPP083 strain; the pediococcus pentosaceus provided by the invention has a relatively strong antibacterial effect, can produce novel IIa bacteriocin, and has the characteristics of acid resistance, high temperature resistance, protease resistance and the like. Genetically engineered bacteria are constructed by using the bacteriocin, and the expression quantity is improved.